Page 104 - Mployee Wellness Programs News Today

Only 44% of Medicare Advantage enrollees said they “fully understand” their plan, while 50% said they “somewhat understand” it and 6% said they don’t understand it, according to a recent survey.

M&A activity in the healthcare sector continued to decline in the second quarter of 2023, with the number of deals reaching its lowest point in three years. However, a new report predicted that M&A activity could increase in the second half of this year due to healthcare companies’ continually shrinking valuations and their divestitures of non-core assets.

Flagship Pioneering-founded Alltrna is developing tRNA therapies to address genetic diseases driven by truncated versions of proteins. By addressing an aberrant genetic instruction underpinning many diseases, the startup is developing what it describes as a potential “universal solution.”

ACA Marketplace insurers are proposing an average 6% premium hike for 2024, with inflation being a driving factor, according to an analysis by KFF.

Senator Mark Warner (D-Virginia) penned a letter to Google leadership expressing concerns about Med-PaLM 2 — the company’s generative AI tool for healthcare providers that is currently being used by Mayo Clinic and other health systems. The letter requested that Google provide more clarity about its chatbot’s training, accuracy, ethical considerations and deployment in healthcare settings.

Traditionally offering family building support, Progyny is expanding into the menopause space. Employees of its employer customers will receive a personalized care plan that includes support for nutrition, sleep, mental health and hormonal health — all factors that affect menopause.

In the future, research in personalized nutrition needs to focus on understanding the role of nutrition throughout the entire lifespan and address diet-related conditions through comprehensive interventions that go beyond simply choosing healthy foods.

Johnson & Johnson’s stable of multiple myeloma drugs has grown to five products with the FDA approval of Talvey. The bispecific antibody is the first in a new class of new drugs designed to go after the novel multiple myeloma target GPRC5D.

“Botched math” in calculating clinical data for an autoimmune disease drug is one of the allegations Nektar Therapeutics makes in a legal complaint against Eli Lilly. The biotech claims its former partner tried to disadvantage the asset in order to advance development of another drug it acquired in a billion dollar deal.

HHS issued an alert warning providers about Rhysida, a ransomware gang that recently begun launching attacks on healthcare organizations. The group deploys its ransomware primarily through phishing attacks or the exploitation of legitimate cybersecurity tools.